Afficher la notice abrégée

Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic

dc.rights.licenseopenen_US
dc.contributor.authorARIZA-VIOQUE, E.
dc.contributor.authorELLO, F.
dc.contributor.authorANDRIAMAMONJISOA, H.
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorMACHAULT, Vanessa
dc.contributor.authorGONZALEZ-MARTIN, J.
dc.contributor.authorCALVO-CORTES, M. C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorEHOLIE, Serge Paul
dc.contributor.authorTCHABERT, G. A.
dc.contributor.authorOUASSA, T.
dc.contributor.authorRABERAHONA, M.
dc.contributor.authorRAKOTOARIVELO, R.
dc.contributor.authorRAZAFINDRAKOTO, H.
dc.contributor.authorRAHAJAMANANA, L.
dc.contributor.authorWILKINSON, R. J.
dc.contributor.authorDAVIS, A.
dc.contributor.authorMAXEBENGULA, M.
dc.contributor.authorABRAHAMS, F.
dc.contributor.authorMUZOORA, C.
dc.contributor.authorNAKIGOZI, N.
dc.contributor.authorNYEHANGANE, D.
dc.contributor.authorNANJEBE, D.
dc.contributor.authorMBEGA, H.
dc.contributor.authorKAITANO, R.
dc.contributor.authorBONNET, M.
dc.contributor.authorDEBEAUDRAP, P.
dc.contributor.authorMIRO, J. M.
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorANGLARET, Xavier
dc.contributor.authorRAKOTOSAMIMANANA, N.
dc.contributor.authorCALMY, A.
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorAMBROSIONI, J.
dc.date.accessioned2022-07-13T12:06:34Z
dc.date.available2022-07-13T12:06:34Z
dc.date.issued2022-06-29
dc.identifier.issn2193-8229 (Print) 2193-6382 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140472
dc.description.abstractEnTuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa. The INTENSE-TBM project aimed to design a comprehensive work-package on capacity building, ensuring all centres would acquire the ability to conduct a phase III randomised clinical trial on TBM in sub-Saharan Africa, to reduce tuberculous meningitis mortality and morbidity in patients with/without HIV-1 co-infection. Therefore, the INTENSE-TBM project is an example of how an international clinical research consortium can provide opportunities to enhance local capacity building and promote centres without previous experience in clinical research. This article provides practical approaches for implementing effective capacity-building programmes. We highlight how to overcome limitations imposed by the COVID-19 pandemic to successfully complete clinics, laboratory set-ups and personnel training, so as to optimise resources and empower African institutions on a local level. At the same time, our experience shows how capacity-building programmes can deliver long-lasting impact that extends beyond the original aims of the project (e.g. HIV and TB), and support local health systems in fighting other infectious disease (e.g. COVID-19). Research projects in low- and lower-middle income countries with heterogeneous settings could stand to benefit the most. eng
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enAfrica
dc.subject.enCapacity building
dc.subject.enClinical research
dc.subject.enHIV
dc.subject.enINTENSE-TBM
dc.subject.enTuberculous meningitis
dc.title.enCapacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s40121-022-00667-zen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35767219en_US
bordeaux.journalInfectious Diseases and Therapyen_US
bordeaux.page1-15en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut National de la Santé et de la Recherche Médicaleen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-03722476
hal.version1
hal.date.transferred2022-07-13T12:07:02Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Infectious%20Diseases%20and%20Therapy&rft.date=2022-06-29&rft.spage=1-15&rft.epage=1-15&rft.eissn=2193-8229%20(Print)%202193-6382%20(Linking)&rft.issn=2193-8229%20(Print)%202193-6382%20(Linking)&rft.au=ARIZA-VIOQUE,%20E.&ELLO,%20F.&ANDRIAMAMONJISOA,%20H.&MACHAULT,%20Vanessa&GONZALEZ-MARTIN,%20J.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_IDT_2022_Ariza-Vioque.pdf
Taille:
4.051Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
920octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée